Co-immunization of rhesus macaques with plasmid vectors expressing IFN-γ, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus

Vaccine

Volumn 20, Issue SUPPL. 4, 2002, Pages

  Lena, P ^a,b   Villinger, F ^c   Giavedoni, L ^d   Miller, C J ^b   Rhodes, G ^a   Luciw, P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Adjuvant; Cytokine; SIV

Indexed keywords

CD4 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PLASMID DNA; PLASMID VECTOR; VIRUS NUCLEOPROTEIN; PRIMER DNA; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; EXPRESSION VECTOR; HUMORAL IMMUNITY; INFECTION CONTROL; INFLUENZA VIRUS; MOUTH MUCOSA; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA; VIRUS INFECTION; VIRUS PATHOGENESIS; ANIMAL; ARTICLE; CD4 LYMPHOCYTE COUNT; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MACACA; NUCLEOTIDE SEQUENCE; PLASMID; SIMIAN IMMUNODEFICIENCY VIRUS; VIRULENCE;

ANIMALS; ANTIGENS, VIRAL; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; DNA PRIMERS; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; LYMPHOCYTE DEPLETION; MACACA MULATTA; PLASMIDS; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRULENCE;

EID: 0037137529     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00391-2     Document Type: Conference Paper

References (33)

1. Cho H.J., Hayashi T., Datta S.K.et al. IFN-alpha beta promote priming of antigen-specific CD8+ and CD4+ T-lymphocytes by immunostimulatory DNA-based vaccines. J. Immunol. 168(10):2002;4907-4913.
2. Akbari O., Panjwani N., Garcia S.et al. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189(1):1999;169-178.
3. Cho J.H., Lee S.W., Sung Y.C. Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granulocyte-macrophage colony-stimulating factor gene in intramuscular DNA immunization. Vaccine. 17(9/10):1999;1136-1144.
4. Sin J., Kim J.J., Pachuk C., Satishchandran C., Weiner D.B. DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J. Virol. 74(23):2000;11173-11180.
5. Barouch D.H., Santra S., Schmitz J.E.et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 290(5491):2000;486-492.
6. Bowne W.B., Wolchok J.D., Hawkins W.G.et al. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines Cell. Mol. Theory. 5(4):1999;217-225.
7. Finbloom D.S., Larner A.C., Nakagawa Y., Hoover D.L. Culture of human monocytes with granulocyte-macrophage colony-stimulating factor results in enhancement of IFN-gamma receptors but suppression of IFN-gamma-induced expression of the gene IP-10. J. Immunol. 150(6):1993;2383-2390.
8. Chapman B.S., Thayer R.M., Vincent K.A., Haigwood N.L. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucl. Acids Res. 19(14):1991;3979-3986.
9. Bray M., Prasad S., Dubay J.W.et al. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc. Natl. Acad. Sci. U.S.A. 91(4):1994;1256-1260.
10. Regier D.A., Desrosiers R.C. The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res. Hum. Retroviruses. 6(11):1990;1221-1231.
11. Felgner P.L., Gadek T.R., Holm M.et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84(21):1987;7413-7417.
12. Hoffman S.L., Crutcher J.M., Puri S.K.et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 3(1):1997;80-83.
13. Kitamura T., Tange T., Terasawa T.et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 140(2):1989;323-334.
14. Oez S., Buhrer C., Atzpodien J., Kalden J.R. A highly sensitive quantitative bioassay for human granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 18(10):1990;1108-1111.
15. Lewis M.G., Bellah S., McKinnon K.et al. Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res. Hum. Retroviruses. 10(2):1994;213-220.
16. Otsyula M.G., Miller C.J., Tarantal A.F.et al. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology. 222(1):1996;275-278.
17. Leutenegger C.M., Higgins J., Matthews T.B.et al. Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res. Hum. Retroviruses. 17(3):2001;243-251.
18. Bostik P., Brice G.T., Greenberg K.P.et al. Inverse correlation of telomerase activity/proliferation of CD4+ T-lymphocytes and disease progression in simian immunodeficiency virus-infected nonhuman primates. J. Acquir. Immune Defic. Syndr. 24(2):2000;89-99.
19. Amara R.R., Villinger F., Altman J.D.et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292(5514):2001;69-74.
20. Heeney J.L., Koopman G., Rosenwirth B.et al. A vaccine strategy utilizing a combination of three different chimeric vectors which share specific vaccine antigens. J. Med. Primatol. 29(3/4):2000;268-273.
21. Feinberg M.B., Moore J.P. AIDS vaccine models: challenging challenge viruses. Nat. Med. 8(3):2002;207-210.
22. Staprans S.I., Dailey P.J., Rosenthal A.et al. Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J. Virol. 73(6):1999;4829-4839.
23. Benson J., Chougnet C., Robert-Guroff M.et al. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIVmac251: dependence on route of challenge exposure. J. Virol. 72(5):1998;4170-4182.
24. Haigwood N.L., Pierce C.C., Robertson M.N.et al. Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol. Lett. 66(1/3):1999;183-188.
25. Ansari A.A., Mayne A.E., Sundstrom J.B.et al. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J. Virol. 76(4):2002;1731-1743.
26. Kumar S., Villinger F., Oakley M.et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody. Immunol. Lett. 81(1):2002;13-24.
27. Somasundaram C., Takamatsu H., Andreoni C.et al. Enhanced protective response and immuno-adjuvant effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky's disease virus. Vet. Immunol. Immunopathol. 70(3/4):1999;277-287.
28. Sykes K.F., Lewis M.G., Squires B., Johnston S.A. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine. 20(17/18):2002;2382-2395.
29. Watanabe N., Sypek J.P., Mittler S.et al. Administration of recombinant human interleukin 12 to chronically SIVmac-infected rhesus monkeys. AIDS Res. Hum. Retroviruses. 14(5):1998;393-399.
30. O'Neil E, Martinez I, Villinger F, et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol 2002, in press.
31. Kusakabe K., Xin K.Q., Katoh H.et al. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J. Immunol. 164(6):2000;3102-3111.
32. Veazey R.S., Tham I.C., Mansfield K.G.et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo. J. Virol. 74(1):2000;57-64.
33. Douek D.C., Brenchley J.M., Betts M.R.et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature. 417(6884):2002;95-98.